Clinical Trials Logo

Epistaxis Nosebleed clinical trials

View clinical trials related to Epistaxis Nosebleed.

Filter by:
  • None
  • Page 1

NCT ID: NCT05937516 Completed - Epistaxis Nosebleed Clinical Trials

Guidewire Use in Nasotracheal Intubation

Start date: March 15, 2023
Phase: N/A
Study type: Interventional

During nasotracheal intubation, nasopharyngeal trauma and associated bleeding may occur. The investigators think that some of this bleeding is due to trauma to the posterior wall of the nasopharynx. The investigators designed this study, thinking that if nasopharyngeal posterior wall trauma can be prevented, some of these bleedings can be prevented.

NCT ID: NCT05789264 Recruiting - Epistaxis Nosebleed Clinical Trials

Nasal Compression Device Study for Epistaxis

Start date: September 26, 2023
Phase: N/A
Study type: Interventional

This study will explore how a nasal compression device compares to manual compression for stopping anterior nosebleeds. This will be a non-randomized controlled trial enrolling participants presenting to medical care for anterior nosebleeds. Participants will be assigned to receive either a nasal compression device or standard of care consisting of digital compression. Participants will be asked to complete survey questions to assess satisfaction with the care they received, comfort, and overall experience with the device.

NCT ID: NCT04646356 Active, not recruiting - Clinical trials for Hereditary Hemorrhagic Telangiectasia

Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

This study will investigate the effectiveness of oral low-dose tacrolimus for the treatment of recurrent nasal hemorrhage in HHT subjects. The primary outcome for the trials will be the reduction of epistaxis severity (minutes of bleeding per week). The biological outcomes of interest are the regression of vascular malformations as well as tissue and circulation biomarkers of the relevant mechanistic pathways. In this Phase II open label trial, we estimate a sample size of 30 subjects with HHT, with moderate-severe recurrent epistaxis will be required. Subject will be treated with a 6-month course of tacrolimus twice daily.